网症的循环标记与COVID-19严重性的关系:一个前性队列研究
Abhyuday Kumar1, Neeraj Kumar1, Ayan Banerjee2
1Department of Anesthesiology, All India Institute of Medical Sciences (AIIMS), Patna, Bihar, India.
中性粒细胞外细胞陷 (NETs) 和它们的标记物,如素化组织素 (Cit-H3),在COVID-19患者中升高. 增加的Cit-H3水平与严重的COVID-19相关,这表明它在疾病进展中的作用.
科学领域:
- 免疫学和传染病的研究
- 细胞生物学和病理学
背景情况:
- 细胞死亡的一种形式,形成中性粒细胞外细胞陷 (NETs),涉及到严重的COVID-19并发症,如ARDS和细胞因子风暴.
- NETs可能会导致关键结果,包括COVID-19患者的血栓栓塞事件和多器官衰竭.
研究的目的:
- 为了调查NETosis标记物 (基素基因素[Cit-H3],骨髓氧化酶[MPO],弹性酶) 和COVID-19之间的关联.
- 评估这些NETosis标志物与COVID-19疾病的严重程度之间的关系.
主要方法:
- 预计将招收99名住院COVID-19患者和30名对照组.
- 在入院时测量血清Cit-H3,MPO和弹性酶水平.
- 在非严重,严重和危急的COVID-19类别中比较标记水平,与PO2/FiO2比率的相关性.
主要成果:
- 与对照组相比,COVID-19患者的Cit-H3和弹性酶水平明显升高.
- 严重的COVID-19病例显示Cit-H3水平明显高于非严重病例.
- 素基因组显示出预测COVID-19严重程度的合理诊断能力 (74%的灵敏度,在34 ng/mL时的64%的特异性).
结论:
- 素基因组独立与COVID-19的严重程度相关,与C-反应蛋白 (CRP) 一起.
- 与NETosis相关的生物标志物与COVID-19疾病进展有关.
- 这些发现支持进一步研究使用NETosis生物标志物针对COVID-19的有针对性的监测策略.
更多相关视频
06:29Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
相关概念视频
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome III: Diagnostic Studies
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease II: Pathophysiology
